SI2054432T1 - Specifični in visokoafinitetno vezavni proteini, ki obsegajo modificirane SH3 domene FYN kinaze - Google Patents

Specifični in visokoafinitetno vezavni proteini, ki obsegajo modificirane SH3 domene FYN kinaze

Info

Publication number
SI2054432T1
SI2054432T1 SI200731691T SI200731691T SI2054432T1 SI 2054432 T1 SI2054432 T1 SI 2054432T1 SI 200731691 T SI200731691 T SI 200731691T SI 200731691 T SI200731691 T SI 200731691T SI 2054432 T1 SI2054432 T1 SI 2054432T1
Authority
SI
Slovenia
Prior art keywords
domains
modified
specific
high affinity
binding proteins
Prior art date
Application number
SI200731691T
Other languages
English (en)
Inventor
Dragan Grabulovski
Dario Neri
Original Assignee
Eidgenoessische Technische Hochschule Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eidgenoessische Technische Hochschule Zuerich filed Critical Eidgenoessische Technische Hochschule Zuerich
Publication of SI2054432T1 publication Critical patent/SI2054432T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
SI200731691T 2006-08-21 2007-08-20 Specifični in visokoafinitetno vezavni proteini, ki obsegajo modificirane SH3 domene FYN kinaze SI2054432T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06017336A EP1892248A1 (en) 2006-08-21 2006-08-21 Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
EP07801764.7A EP2054432B1 (en) 2006-08-21 2007-08-20 Specific and high affinity binding proteins comprising modified sh3 domains of fyn kinase
PCT/EP2007/007324 WO2008022759A2 (en) 2006-08-21 2007-08-20 Specific and high affinity binding proteins comprising modified sh3 domains of fyn kinase

Publications (1)

Publication Number Publication Date
SI2054432T1 true SI2054432T1 (sl) 2015-10-30

Family

ID=37074627

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731691T SI2054432T1 (sl) 2006-08-21 2007-08-20 Specifični in visokoafinitetno vezavni proteini, ki obsegajo modificirane SH3 domene FYN kinaze

Country Status (19)

Country Link
US (1) US20100119446A1 (sl)
EP (2) EP1892248A1 (sl)
JP (2) JP2010500875A (sl)
KR (1) KR101159903B1 (sl)
CN (2) CN101506230A (sl)
AU (1) AU2007287807B2 (sl)
BR (1) BRPI0715818B8 (sl)
CA (1) CA2661160C (sl)
CY (1) CY1116952T1 (sl)
DK (1) DK2054432T3 (sl)
ES (1) ES2548438T3 (sl)
HU (1) HUE027941T2 (sl)
MX (1) MX2009001867A (sl)
NZ (1) NZ574889A (sl)
PL (1) PL2054432T3 (sl)
PT (1) PT2054432E (sl)
RU (1) RU2478707C2 (sl)
SI (1) SI2054432T1 (sl)
WO (1) WO2008022759A2 (sl)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
EP1925664A1 (en) 2006-11-15 2008-05-28 Scil proteins GmbH Artificial binding proteins based on a modified alpha helical region of ubiquitin
ATE542830T1 (de) 2006-12-04 2012-02-15 Pasteur Institut Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel
EP2470556B1 (en) * 2009-08-27 2018-05-30 Covagen AG Il-17 binding compounds and medical uses thereof
CA2777883A1 (en) 2009-10-21 2011-04-28 Eth Zurich Medical utility of glycan-binding proteins and glycans
ES2441803T3 (es) 2009-12-14 2014-02-06 Scil Proteins Gmbh Un método para identificar proteínas de ubicuitina heteromultímeras modificadas con capacidad para unirse a ligandos
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
CN102174478B (zh) * 2011-01-05 2014-08-06 复旦大学 一种光敏剂结合蛋白/多肽及其在光动力基因治疗中的应用
EP2524927A1 (en) * 2011-05-20 2012-11-21 Covagen AG New chymase binding compounds and medical uses thereof
WO2012172055A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Dimeric binding proteins based on modified ubiquitins
WO2012171541A1 (en) * 2011-06-15 2012-12-20 Scil Proteins Gmbh Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
EP2597102A1 (en) 2011-11-25 2013-05-29 Covagen AG A novel fusion protein comprising an antibody light chain and a polypeptide binding to IL-17
WO2013135588A1 (en) * 2012-03-16 2013-09-19 Covagen Ag Novel binding molecules with antitumoral activity
EP2638916A1 (en) 2012-03-16 2013-09-18 Covagen AG Novel binding molecules with antitumoral activity
EP2711016A1 (en) 2012-09-21 2014-03-26 Covagen AG Novel IL-17A binding molecules and medical uses thereof
EP2752426A1 (en) * 2013-01-03 2014-07-09 Covagen AG Human serum albumin binding compounds and fusion proteins thereof
WO2014111458A2 (en) 2013-01-17 2014-07-24 Medizinische Hochschule Hannover Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
CA2907338C (en) * 2013-03-15 2019-09-17 Asieris Pharmaceutical Technologies Co., Ltd. Base addition salts of nitroxoline and uses thereof
AU2014256037B2 (en) * 2013-04-19 2017-09-21 Covagen Ag Novel bispecific binding molecules with antitumoral activity
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
EP2913671A1 (en) 2014-02-27 2015-09-02 Leukocare Ag Novel coated carriers for the specific binding of target molecules
EP2998396A1 (en) 2014-09-16 2016-03-23 Technische Universität Dresden Manipulation of hairy and enhancer of split 3 (Hes3) and its regulators/mediators in diabetes, obesity, and metabolic syndrome
EP3970748A1 (en) 2014-12-24 2022-03-23 NexImmune, Inc. Nanoparticle compositions and methods for immunotherapy
DK3253785T3 (da) 2015-02-06 2019-07-08 Navigo Proteins Gmbh Hidtil ukendte egfr-bindingsproteiner
FI126633B (en) 2015-07-10 2017-03-15 Next Biomed Therapies Oy Method of Preparation of a Library comprising Recombinant Derivatives of the SH3 Domain of Nephrocystin (NPHP1)
AU2016293063B2 (en) 2015-07-16 2018-11-08 Navigo Proteins Gmbh Novel immunoglobulin-binding proteins and their use in affinity purification
US10584152B2 (en) 2015-07-20 2020-03-10 Navigo Proteins Gmbh Binding proteins based on di-ubiquitin muteins and methods for generation
EP3371311B1 (en) 2015-11-06 2021-07-21 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
KR20180081608A (ko) 2015-11-19 2018-07-16 아스클리픽스 테라퓨틱스, 엘엘씨. 항-혈관형성, 항-림프관신생, 및 항-부종성 특성을 가진 펩티드 및 나노입자 제제
US10988538B2 (en) 2016-02-05 2021-04-27 Orionis Biosciences BV Bispecific signaling agents and uses thereof
JP2019507762A (ja) 2016-03-07 2019-03-22 ブイアイビー ブイゼットダブリュー Ｃｄ２０結合単一ドメイン抗体
AU2017260274A1 (en) 2016-05-04 2018-11-01 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
JP7105200B2 (ja) 2016-05-13 2022-07-22 オリオニス バイオサイエンシズ ビーブイ 標的突然変異体インターフェロン－ベータおよびその使用
WO2017194782A2 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Therapeutic targeting of non-cellular structures
WO2017202851A1 (en) 2016-05-23 2017-11-30 Technische Universität München Secretin receptor agonists to treat diseases or disorders of energy homeostasis
CN105907760A (zh) * 2016-05-31 2016-08-31 东北师范大学 靶向沉默TKS4的shRNA
US10786509B2 (en) 2016-06-30 2020-09-29 Siess Wolfgang Treatment and prevention of atherothrombosis by inhibition of bruton's tyrosine kinase (BTK)
WO2018002311A1 (en) 2016-06-30 2018-01-04 Siess Wolfgang Treatment and prevention of atherothrombosis by inhibition of syk kinase
JP7181612B2 (ja) 2016-08-11 2022-12-01 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツング アルカリ安定性免疫グロブリン結合タンパク質
KR20190066040A (ko) 2016-10-04 2019-06-12 아스클리픽스 테라퓨틱스, 인크. Tie2 신호전달을 활성화시키기 위한 화합물 및 방법
ES2917000T3 (es) 2016-10-24 2022-07-06 Orionis Biosciences BV Interferón-gamma mutante diana y usos del mismo
WO2018144999A1 (en) 2017-02-06 2018-08-09 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
EP3577133A1 (en) 2017-02-06 2019-12-11 Orionis Biosciences NV Targeted chimeric proteins and uses thereof
US11246911B2 (en) 2017-02-07 2022-02-15 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
US10722589B2 (en) 2017-04-03 2020-07-28 Covagen Ag FGFR3 binding molecules
WO2019028427A1 (en) 2017-08-03 2019-02-07 Asclepix Therapeutics, Llc. METHODS OF IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE TIE2 RECEPTOR
US20190153096A1 (en) 2017-10-02 2019-05-23 Covagen Ag Cd3/cd33 bispecific binding molecules
US20190100587A1 (en) 2017-10-02 2019-04-04 Covagen Ag IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
US11414466B2 (en) 2017-11-07 2022-08-16 Navigo Proteins Gmbh Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer
EP3749295A4 (en) 2018-02-05 2022-04-27 Orionis Biosciences, Inc. FIBROBLAST BINDING AGENTS AND USES THEREOF
KR20200121844A (ko) 2018-02-16 2020-10-26 비.알.에이.아이.엔. 바이오테그놀로지 리서치 앤드 인포메이션 네크워크 아게 표피 각질세포의 분화를 변화시키는 데 사용하기 위한 vrac 단백질 lrrc8a
US20210238690A1 (en) 2018-04-26 2021-08-05 Intellexon Gmbh Hla-j and medical/diagnostic uses thereof
WO2019233605A1 (en) * 2018-06-08 2019-12-12 BioNTech SE Compositions and methods for diagnosis and treatment of cancer
WO2020058277A1 (en) 2018-09-19 2020-03-26 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Site-specific serine adp-ribosylated proteins and peptides and method for producing the same
US20220074954A1 (en) 2018-12-19 2022-03-10 Medizinische Universität Wien Means and method for the early prediction of poor neurological outcome in out-of-hospital cardiac arrest survivors
EP3693380A1 (en) 2019-02-11 2020-08-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Dual inhibition of plexin-b1 and plexin-b2
EP3924389A4 (en) 2019-02-15 2023-06-14 Integral Molecular, Inc. CLAUDIN-6 ANTIBODIES AND THEIR USES
CA3129317A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
EP3715370A1 (en) 2019-03-28 2020-09-30 Technische Universität München High affinity anticalins directed against human cd98hc
AU2020309312A1 (en) 2019-07-05 2022-01-27 Intellexon Gmbh Methods for diagnosing the effectiveness of anti-tumor treatment
CN114341172A (zh) 2019-07-05 2022-04-12 英特莱克森有限责任公司 医学和诊断学中的hla-h
US20220267379A1 (en) 2019-07-15 2022-08-25 Ecole Polytechnique Federale De Lausanne (Epfl) Novel inhibitors of kallikrein proteases and uses thereof
EP3766894A1 (en) 2019-07-15 2021-01-20 Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO Novel inhibitors of kallikrein proteases and uses thereof
CN114746547A (zh) 2019-09-23 2022-07-12 洛桑联邦政府综合工科学校（Epfl) 通过抑制鞘脂类治疗和预防衰老相关疾病和/或衰老
JP2022553073A (ja) 2019-10-25 2022-12-21 インテレクソン ゲゼルシャフト ミット ベシュレンクテル ハフツング 治療・診断標的としてのｈｌａ－ｈ， ｈｌａ－ｊおよびｈｌａ－ｌ
KR20220088882A (ko) 2019-10-25 2022-06-28 인텔렉슨 게엠베하 시험관 수정에서 hla 클래스 i 분자 및 추가적인 의학적 의미
EP4073111A1 (en) 2019-12-11 2022-10-19 Cilag GmbH International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
GB202004514D0 (en) 2020-03-27 2020-05-13 Inst De Medicina Molecular Joaeo Lobo Antunes Treatment of Immunosuppressive Cancer
WO2021259909A1 (en) 2020-06-22 2021-12-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Generation of trophectoderm-like cells and assembly of trophectoderm-like vesicles and synthetic embryoids
US20240052359A1 (en) 2021-02-10 2024-02-15 Limagrain Europe Multiplex targeted recombinations for trait introgression applications
GB202101932D0 (en) 2021-02-11 2021-03-31 Norwegian Univ Sci & Tech Ntnu Products and methods for promoting myogenesis
WO2022195042A1 (en) 2021-03-18 2022-09-22 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Protein having hdgf (hepatoma-derived growth factor) function for use in treating and preventing neurodegenerative diseases
EP4337700A1 (en) 2021-05-12 2024-03-20 Technische Universität München Humanized anti-psma antibody
KR20220157686A (ko) 2021-05-21 2022-11-29 주식회사 지놈앤컴퍼니 항-bcam 항체 또는 그의 항원 결합 단편
CA3223953A1 (en) 2021-07-29 2023-02-02 Katharina HOFER Rnaylation
EP4137503A1 (en) 2021-08-20 2023-02-22 École Polytechnique Fédérale de Lausanne (EPFL) Novel cathepsin inhibitors
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
EP4239061A1 (en) 2022-03-03 2023-09-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the generation of outer radial glial (org) cells
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
EP4299119A1 (en) 2022-06-29 2024-01-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Therapeutic applications based on the inhibition of g protein-coupled receptor 182 (gpr182)
WO2024003205A1 (en) 2022-06-30 2024-01-04 Medizinische Hochschule Hannover Long non-coding rnas as target for treating fibrosis and cancer
WO2024008755A1 (en) 2022-07-04 2024-01-11 Vib Vzw Blood-cerebrospinal fluid barrier crossing antibodies
WO2024052434A1 (en) 2022-09-06 2024-03-14 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Engineering sox/oct heterodimerization to induce high-grade developmental reset

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3404246A1 (de) * 1984-02-07 1985-08-14 Krauss-Maffei AG, 8000 München Reinigungsvorrichtung fuer rohrwaffen
US6326469B1 (en) * 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
CA2389062A1 (en) * 1999-10-29 2001-05-10 Ssp Co., Ltd. Human protein which binds to human tyrosine kinase hck, and gene encoding the same
ES2312478T3 (es) * 2000-09-07 2009-03-01 Bayer Schering Pharma Aktiengesellschaft Receptor del dominio edb de fibronectina (ii).
AUPR688101A0 (en) * 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
EP1470240A4 (en) * 2002-02-01 2006-08-30 Millennium Pharm Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES USING 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419 , 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2
AU2003289716A1 (en) * 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
WO2004042022A2 (en) * 2002-11-01 2004-05-21 Incyte Corporation Kinases and phosphatases
WO2005000887A1 (en) * 2003-06-30 2005-01-06 Universite De Lausanne Rasgap derived peptide for selectively killing cancer cells
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1541694A1 (en) * 2003-12-12 2005-06-15 Sirenade Pharmaceuticals AG Methods of identifying, selecting and/or characterizing compounds which modulate the activity of a Src family kinase
WO2007030426A2 (en) * 2005-09-07 2007-03-15 Board Of Regents, The University Of Texas System Methods of using and analyzing biological sequence data

Also Published As

Publication number Publication date
KR20090053926A (ko) 2009-05-28
WO2008022759A3 (en) 2008-04-17
CY1116952T1 (el) 2017-04-05
BRPI0715818B8 (pt) 2021-05-25
NZ574889A (en) 2011-11-25
WO2008022759A2 (en) 2008-02-28
RU2478707C2 (ru) 2013-04-10
PT2054432E (pt) 2015-10-15
DK2054432T3 (en) 2015-09-14
BRPI0715818A2 (pt) 2013-07-23
PL2054432T3 (pl) 2015-11-30
ES2548438T3 (es) 2015-10-16
MX2009001867A (es) 2009-03-03
EP1892248A1 (en) 2008-02-27
BRPI0715818B1 (pt) 2020-04-22
HUE027941T2 (en) 2016-11-28
KR101159903B1 (ko) 2012-06-26
AU2007287807B2 (en) 2011-10-13
EP2054432A2 (en) 2009-05-06
CN101506230A (zh) 2009-08-12
CA2661160C (en) 2016-11-08
CA2661160A1 (en) 2008-02-28
JP2010500875A (ja) 2010-01-14
AU2007287807A1 (en) 2008-02-28
CN103087172A (zh) 2013-05-08
US20100119446A1 (en) 2010-05-13
JP2013078316A (ja) 2013-05-02
EP2054432B1 (en) 2015-07-15
JP5726837B2 (ja) 2015-06-03
RU2009110180A (ru) 2010-09-27

Similar Documents

Publication Publication Date Title
SI2054432T1 (sl) Specifični in visokoafinitetno vezavni proteini, ki obsegajo modificirane SH3 domene FYN kinaze
ZA200704888B (en) Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
EP2057465A4 (en) SPECIFIC ORGAN PROTEINS AND METHODS OF USE
AP2007003974A0 (en) Prion protein binding materials and methods of use
IL197061A0 (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
HK1216486A1 (zh) 蛋白飲料及其製備方法
GB0902572D0 (en) Activatable binding polypeptides and methods of indentifcation and use thereof
HK1130057A1 (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners bcl
EP1931205A4 (en) TRANSGLUTAMINASE INHIBITORS AND METHOD OF USE THEREOF
EP2102355A4 (en) PROTEINS AND PEPTIDES WITH EXTENDED ACTION AND METHODS OF PRODUCTION AND USE THEREOF
EP2076128A4 (en) PROTEIN CHINESE INHIBITOR AND ITS USE METHOD
EP2155228A4 (en) POLYPEPTIDE INHIBITORS OF HSP27 KINASE AND USES THEREOF
EP2029799A4 (en) THERMOSTABLE PROTEINS AND METHODS FOR PREPARING AND USING SAME
EP1981888A4 (en) TYROSINE KINASE INHIBITORS AND USES THEREOF
EP2193145A4 (en) COMPOSITIONS AND METHODS COMPRISING BINDING PROTEINS FOR ADALIMUMAB
HK1137448A1 (en) Serine-threonine protein kinase and parp modulators - parp
IL219654A0 (en) Binding proteins that bind hepatocyte growth factor and methods of producing the same
GB0601102D0 (en) Kinase Peptides And Antibodies
EP1908482A4 (en) STABILIZER FOR PROTEIN PREPARATION WITH MEGLUMIN AND ITS USE
IL194161A0 (en) Tetramerizing polypeptides and methods of use
EP1877424A4 (en) INHIBITORS OF PROTEIN KINASES AND USES THEREOF
EP1922086A4 (en) TARGETED PROTEIN KINASE C HEMMER AND ITS USES
ZA201003420B (en) Protein kinase inhibitors and use thereof
IL188611A (en) Type 1sp polypeptides are altered at the n-terminal end and used
IL207415A0 (en) Protein kinase inhibitors and use thereof